Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study

Background: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. Methods: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. Results: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. Conclusions: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects.

Yazar Araz, Omer
Demirci, Elif
Ucar, Elif Yilmazel
Calik, Muhammet
Pulur, Didem
Karaman, Adem
Yayla, Muhammed
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/2277
Tek Biçim Adres 10.1186/2049-6958-8-74
Konu Başlıkları Acute lung injury
Bosentan
Dexamethasone
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı MULTIDISCIPLINARY RESPIRATORY MEDICINE
Dergi Cilt Bilgisi 8
Sayfalar -
Yayın Yılı 2013
Eser Adı
[dc.title]
Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study
Yazar
[dc.contributor.author]
Araz, Omer
Yazar
[dc.contributor.author]
Demirci, Elif
Yazar
[dc.contributor.author]
Ucar, Elif Yilmazel
Yazar
[dc.contributor.author]
Calik, Muhammet
Yazar
[dc.contributor.author]
Pulur, Didem
Yazar
[dc.contributor.author]
Karaman, Adem
Yazar
[dc.contributor.author]
Yayla, Muhammed
Yayın Yılı
[dc.date.issued]
2013
Yayıncı
[dc.publisher]
BMC
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. Methods: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered orally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. Results: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. Conclusions: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects.
Açıklama
[dc.description]
WOS: 000330182500001
Açıklama
[dc.description]
PubMed: 24342001
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Acute lung injury
Konu Başlıkları
[dc.subject]
Bosentan
Konu Başlıkları
[dc.subject]
Dexamethasone
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
2049-6958
Dergi Adı
[dc.relation.journal]
MULTIDISCIPLINARY RESPIRATORY MEDICINE
Dergi Cilt Bilgisi
[dc.identifier.volume]
8
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1186/2049-6958-8-74
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/2277
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
13
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
07 Şubat 2024 22:57
Google Kontrol
Tıklayınız
(Group treatment bosentan alveolar significant injury infiltration hemorrhage dexamethasone Bosentan thickening efficacy parameters resulted administered saline improvements inflammation leukocyte therapies effects reparative before destruction/emphysematous appearance mononuclear organization Background Conclusions reducing choice recommended treating effective criteria
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms